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Eis Goulmy, Dept of Immunohaematology and
Blood Bank, University Hospital Leiden, The
Netherlands.
Graft-versus-Host-Disease (GvHD) still forms a
major barrier to successful Bone Marrow
Transplantation (BMT) between HLA matched as
well as between HLA identical BM
donor/recipient pairs. It is well believed that
disparities for minor Histocompatibility antigens
(mHag) between Β Μ donor and recipient create
a potential risk for GvHD (1,2).
Assuming that as in the mouse, the human
genome has an abundancy of mH loci,
Identification of the "majors" under the "minors"
is a prerequisite. Α 'major' minor distinghuishes
itself through its population frequency,
immunodominancy and tissue distribution. These
prerequisites have been analysed lately by our
group for a small number of mHag. Here we will
briefly summarize the results of these studies
and discuss them in view of the clinical data. In
addition, new aspects on the nature of human
mHag will be discussed as well.
Immunogenetic studies of five non-sexlinked
mHag (designated HA-1 to HA-5) revealed that
some mHag appearedfrequent (69-95%), others
occurred with lesser frequencies (7-16%) in the
healthy population (3). It should be noted that
mHag HA-1 has a phenotype frequency of 69%
in the population, so an HA-1 mismatch between
HLA identical or matched donor/recipient
combinations is likely to occur. An analysis of
the genetic traits of mHag HA-1 to HA-5
demonstrated that they segregate in a
Mendelian fashion. Each of them can be
considered as a product of a Single gene with
two alleles, one expressing and one not
expressing the detected specificity. The loci
encoding the mHag are not closely linked to
HLA (4).
Three sets of data are indicative for a hierarchy
in immunogenicity among mHag. Firstly, CTL
clones reactive to the same mHag HA-1 were
obtained from peripheral blood lymphocytes of
3 out of 5 individuals each transplanted across
a multiple and probably distinct mH barrier (see
table 1 and ref. 3).
Table 1
MINOR Η
Patient
CTL line
Patient 1
HA-1
Patient 2
HA-2
Patient 3
HA-3
Patient 4
HA-4
Patient 5
HA-5
ΑΝΤΙΘΕΝ SPECIFIC CTL
N. of clones
N=7
N=9
N=17
Ν =20
Ν=27
Ν =20
N= 8
N=10
N=11
N= 4
N=11
N=16
mHaq
HA-1
HA-?
HA-2
HA-?
HA-3
HA-?
HA-4
HA-1
HA-?
HA-5
HA-1
HA-?
CLONINQ
% pop. frea
69%
95%
88%
16%
69%
7%
69%
Secondty, we analysed the composition of the Τ cell
receptor (TCR) V regions of twelve of the latter HLA-
A2 restricted mHag HA-1 specific CTL clones
derived from three unrelated patients suffering from
GvHD. Most surprising, the Vß regions, but not the
TCR Va and Ja genes, of the TCR specific for the
HLA-A2/mHag HA-1 complex expressed by all
twelve CTL clones share extensive sequence
homologies (5). These observations support our
notion on the (in vitro) immunogenic potency of the
MHC/mHag HA-1 complex. Moreover, we noticed a
limited TCR repertoire usage among the CTL clones
analysed. Several CTL clones, obtained from
independent limiting dilutions and from different
unrelated patients, shared fully identical TCR α and
ß sequences (5), which could be indicative for a
dominant mHag specific Τ cell response occurring
during the development of GvHD post-BMT.
Thirdly, in an international collaborative1 study,
comprising 148 bone marrow HLA identical
donor/recipient pairs, investigating the influence of
mHag HA-1 to HA-5 mismatching on the
development of GvHD, we observed a significant
correlation between mHag HA-1, -2, -4 and -5
mismatch and GvHD (6). In view of the population
frequency of HA-1, analysis of solely mHag HA-1
mismatch and occurrence of GvHD in adult
patients appeared significant
(table 2).
Table 2.
Corretetion of mHag HA-1 with the occuronce
cfGvHD
Adult patient mHag
GvHD
No
Yes
match
22
49
mismatch
0
10
Ρ = 0.033
Clinical relevance of anti-host CTLs in the
pathogenesis of GvHD. Bone marrow derived Τ
lymphocytes are responsible for anti-host mHag
specific reactivities. Little is known about the
basis of the Τ cell responses mHag evoke in
BMT, although controversies regarding the role
of anti-host CTLs in the development of GvHD
after BMT do exist. In our earlier studies, we
demonstrated the presence of anti-host mHag
specific CTLs in the blood of patients
undergoing GvHD. Although patients with
chronic GvHD tended to deveiop higher and
more persistent levels of anti-host CTL activity
than those without GvHD, this finding was not
statistically significant (7). Subsequent analyses
at the quantitative level i.e. determination of the
frequencies of anti-host specific CTL precursors
revealed high frequencies of mHag specific
CTLs detectable in the blood early after BMT
irrespective of the GvHD Status of the patient
(8). We have therefore, recently started to
investigate, whether we could find qualitative
differences in the anti-host CTLs in patients with
and without GvHD. Based on earlier studies in
kidney grafting where the in vitro resistance in a
Mixed Lymphocyte culture response for the
immunosuppressivedrug Cyclosphorine Α (CsA)
was correlated with a higher rate of graft loss
(9), we analysed the in vitro sensitivity of the
anti-host CTLs for CsA. Patients (N = 12) were
divided into different groups according to their
GvHD Status. PBLs were isolated before and at
several dates after HLA genotypically identical BMT
and used to determine CTLp frequencies of each
patient in (imrting dilution assays, with and without
the addition of CsA to the test medium. The CTLp
frequency of patients without GvHD could all be
inhibited very well by CsA at all dates. However, the
CTLp frequency in patients with acute GvHD could
not be inhibited by CsA at most dates after
transplantation. The CTLp frequency of patients with
chronic GvHD could in some cases not be inhibited,
in others it was inhibited, but always less than in no
GvHD patients. Sofar, our results show that CsA
resistant CTLs are mainly found in patients suffering
from (acute) GvHD. This strongly suggeststhatthey
play an important role in the pathogenesis of GvHD
(10). Our future aim is to confirm this phenomenon
by analyzing more patients and to characterize
these CsA resistant CTLs.
Towards the nature of human mHag. Naturally, an
answer to the question what mH antigens are is
really needed. It would not only reveal their
physiological nature but more importantly provide
inside into their putative role in organ and bone
marrow transplantation. We therefore aimed at the
biochemical characterisation of human mH antigens.
Hereto, we made use of the immunopurification and
biochemical techniques succesfully applied by
Rammensee and his colleagues to extract murine
mH peptides from MHC molecules. Indeed, HPLC
Separation of Iow Mr molecules ( < 10 kD) obtained
from acid treated MHC class I HLA-A2.1 molecules
appeared successful. Fractions with sensitizing
activity for the non-sexlinked mH artigen HA-2
specific CTL clones were isolated (11). Our
observations are in line with previous reports on the
Isolation of naturally occurring peptides that
represented classical murine mH antigens i.e. H-Y
and H-4 (12, 13). Similar to our own results,
Sekimata et al. isolated an human mH antigenic
peptide from EBV-LCLs by acid elution. This HLA-
B35 restricted mH artigen was earlier shown to play
a role in HLA identical kidney graft rejection (14).
Further characterization i.e. exact amino acid
sequence and identity of the protein from which
murine or human mH antigens originate remain to
be determined.
Although the amino acid is not available yet, we do
know that mHag HA-1 and HA-2 are of peptidic
nature. Two sets of data underline this
Statement. First, the sensitizing activity of the
mHag containing fractions, obtained as
described above, are susceptible to protease
treatment (15); i.e. incubation of these mHag
containing HPLC fractions with pronase or
proteinase Κ abolished the sensitizing activity.
Second, the MHC encoded TAP1 and TAP2
gene products are required for mHag peptide
presentation on the cell surface. The transporter
genes TAP1 and TAP2 associated with artigen
presentation are required for delivery of peptides
from the cytosol with the endoplasmic reticulum
(16). The availibility of a human celline "T2"
lacking both transport and proteasome subunit
genes enabled us to study the processing and
presentation of human mH artigens. We
demonstrated that the (rat) transport gene
products TAP1 and TAP2a were required for
processing and presentation of arrtigenic
peptides from influenza virus and from the
intracellular mH protein HA-2 (table 3 and ref.
17). It must be noted that reconstitution and
thus presentation of mHag HA-2 to rts relevant
Τ cell clone was performed with the rat TAP2a
allele. As can be seen from table 3 restoration of
presentation of mHag HA-1 did not occur. In the
rat, polymorphism of the TAP genes have been
observed (18). Subsequent cotransfection into
the T2 cell line of the rat TAP2" (cim b) allele
instead of the TAPa (cim a) allele resulted in
presentation and thus recognrtion of mHag HA-1
(and HA-2) on the cell surface (table 3).
Table 3
mHag require TAP gene products for their
Präsentation
Tarqet cells
T1
T2
T2/TAP1
T2/TAP2
T2/TAP1 +2a
T2/TAP1+2U
A2.1
96°
100
100
81
82
78
Effector cells
HA-1
68
3
1
1
7
71
I HA-2
71
0
0
5
57
73
Q6
62
8
12
5
33
n.t
* influenza virus specific
0
 % lysis at an effector/target ratio of 10 : 1
Taken together, these results show that mHag HA-1
and HA-2 are cytosolic peptides and require TAP
gene products to be transported over the
endoplasmic reticulum where they associate with
newly sensitized class I molecules. It also
demonstrate that HA-1 and HA-2 are different
peptides. Powis et al. (18) showed the effect of TAP
polymorphism on the peptide composition. Reverse-
phase HPLC analysis of peptides eluted from TAPa
versus TAP2U molecules demonstrated different
peptide profiles.
In conclusion, although the number of mH Systems
is expected to be large, probably only a limited
number will fulfil the criteria (i.e. frequency,
immunogenicity, tissue distribution) for being a risk
factor for GvHD or rejection. To dissect the majors
from the minor minors yet more Information is
needed on the Th and CTL defined human mH
artigens repertoire in order to establish the
immunodominant ones. To understand their
biological role in bone marrow transplantation
Information on their cytokine secretation profiel is
also essential. Finally, once the nature of the human
mHag is established the search for immunological
relevant mH families will hopefully accelerate.
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